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Abstract: Streptococcus suis is a swine pathogen and a zoonotic agent afflicting people in close
contact with infected pigs or pork meat. Sporadic cases of human infections have been reported
worldwide. In addition, S. suis outbreaks emerged in Asia, making this bacterium a primary health
concern in this part of the globe. In pigs, S. suis disease results in decreased performance and
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increased mortality, which have a significant economic impact on swine production worldwide.
Facing the new regulations in preventive use of antimicrobials in livestock and lack of effective
vaccines, control of S. suis infections is worrisome. Increasing and sharing of knowledge on this
pathogen is of utmost importance. As such, the pathogenesis and epidemiology of the infection,
antimicrobial resistance, progress on diagnosis, prevention, and control were among the topics
discussed during the 4th International Workshop on Streptococcus suis (held in Montreal, Canada,
June 2019). This review gathers together recent findings on this important pathogen from lectures
performed by lead researchers from several countries including Australia, Canada, France, Germany,
Japan, Spain, Thailand, The Netherlands, UK, and USA. Finally, policies and recommendations for the
manufacture, quality control, and use of inactivated autogenous vaccines are addressed to advance
this important field in veterinary medicine.
Keywords: Streptococcus suis; swine; zoonosis; epidemiology; genomics; diagnosis; antimicrobials;
vaccines; public health; vaccine policies
1. Introduction
Streptococcus suis is considered one of the most important bacterial swine pathogens leading to
important economic losses to the porcine industry worldwide. S. suis has been reported globally
in both traditional and intensive swine operations [1]. Control is based on an alarming overuse of
antimicrobials, leading to a dramatic increase of the risk related to antimicrobial resistance. It is also an
agent of disease in humans and considered in most OECD (Organisation for Economic Co-operation and
Development) countries as an occupational disease affecting mostly swine industry workers. In Asia,
this pathogen affects the general population and represents a significant public health concern [2].
After a deadly 2005 Chinese human outbreak, research teams worldwide turned their attention to
S. suis with an explosion of published articles (Figure 1).
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In 2013, the 1st International Workshop on S. suis was organized with the aim to increase
international collaborations. Since then, the upsurge of studies certainly contributed to our
understanding of bacterial–host interactions. However, the use of different research models resulted in
misconceptions and complicated diagnostics and vaccine development [3,4]. Eight years after the 1st
workshop and after two other workshops (2014 and 2016), the 4th International Workshop on S. suis
was organized to strengthen scientific knowledge and provide, through international cooperation,
relevant scientific information, and advice that will have a direct influence on the decisions made by
the swine industry.
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The diagnosis and epidemiology of the infection in humans and pigs; different aspects of the
pathogenesis of the disease; antimicrobial resistance, prevention and control; and finally autogenous
vaccine policy were addressed during the meeting and are further discussed below.
2. Diagnosis and Epidemiology of the S. suis Infection in Humans and Pigs
S. suis is an encapsulated pathogen, and the capsular polysaccharide (CPS) antigen is the basis of
S. suis classification into serotypes [1]. Originally, 35 serotypes were identified. However, phylogenetic
and/or sequence analyses showed that the reference strains of serotypes 20, 22, 26, 32, 33, and 34
should be taxonomically removed from the S. suis species. Serotypes 32 and 34 were reclassified as
Streptococcus orisratti. Serotypes 20, 22, and 26 were proposed as Streptococcus parasuis, while serotype 33
was classified as Streptococcus ruminantium [5–7]. Nevertheless, more extensive studies using a higher
number of S. suis and S. suis-like strains will provide additional insights into the classification of these
strains and make the species boundaries clearer [6]. In fact, all 35 serotypes of S. suis (or S. suis-like
strains) (with the exception of serotype 33) are isolated from diseased pigs [1], and from the clinical
point of view, many diagnostic laboratories still identify the 35 serotypes. The tools for molecular
epidemiology of S. suis have been recently reviewed in Reference [7].
The worldwide distribution of major S. suis serotypes involved in swine clinical cases is
schematically represented in Figure 2. Among those reported, serotype 2 is considered the most
common cause of infections in piglets worldwide and a major zoonotic agent [2]. Nevertheless,
other serotypes are increasing in importance in different countries, as is the case of serotype 9,
particularly in some countries of Western Europe. By means of novel animal models and diagnostic
tools, de Greeff et al. (Appendix A) epidemiologically determined the population genetics of S. suis
serotype 9 in The Netherlands [8]. Obtained data using comparative genome hybridization and whole
genome sequencing suggest that clinical serotype 9 swine isolates are genetically very similar whereas
serotype 9 isolates carried by healthy pigs are more heterogeneous. A few carriage isolates clustered
together with clinical isolates; these carriage isolates probably reflect clinical isolates that are not
causing any clinical outbreaks on the farms but do have virulent potential. By infecting Caesarean
Derived Colostrum Deprived (CDCD) piglets intravenously with a high dose of bacteria, it was shown
that, within S. suis serotype 9, the virulence of clinical and tonsillar carriage isolates differs significantly
(Appendix A). Interestingly, a recent study indicated that S. suis isolates associated with disease in pigs
comprise predominantly of serotypes 2, 3, and 1/2 (Appendix B), which is consistent with reports from
other pig producing countries [2].
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In Figure 2, it can also be appreciated that the epidemiological situation in North America is
different from other countries. In this part of the globe, multiple serotypes are found in swine clinical
cases [2]. Indeed, recent works confirmed that a variety of S. suis serotypes can be found in commercial
swine production systems in USA and Canada, with serotypes 1/2, 7, 2, 1, 3, and 5 commonly isolated
from systemic infection sites, the frequencies depending on the study [9,10].
Besides this classification based on CPS antigen/gene locus, S. suis is genetically differentiated into
sequence types (ST) by multilocus sequence typing (MLST) [7]. The distribution of most important STs
within serotype 2 is represented in Figure 3.
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multiloc s sequence typing (MLST): ST1 serotype 2 trains are mostly a sociated with disease in both
pigs (where data are available) and humans in Eu pe, Asia, Afric , and South America. The situation is
different in No th Ame ic , where fewer clinical ST1 cases of infection in pigs and only one human ST1
case has been described. ST7, a single locus variant of ST1, is endemic to mainla d China. Interestingly,
Japan and Thailand are the only countries reporting ST28 human cases [2]. “?” m ans no dat available
from swine clinical cases.
It is important to note that epidemiological data is missing for several countries; for example,
information relating to S. suis in the Australian pig herd is li ited [11,12]. To fill this gap, O’Dea et
al. (Appendix B) analysed and characterised a significant number of S. suis isolates from diseased
pigs obtained across multiple production sites over a seven year period [13]. The most pro inent
MLSTs were, in decreasing order, ST27, ST25, ST28, ST483, and ST1. Analysis of serotype and MLST
combinations showed a high proportion of isolates as serotype 2 ST25, serotype 3 ST27, and serotype 2
ST28. A deeper phylogenetic comparison of the S. suis isolates from Australian pigs against a global
collection of S. suis strains showed that Australian clones of S. suis associated with clinical disease in
pigs have maintained a stable core genome, mirroring the international seed-stock from which they
were derived ( ainly from the UK and North A erica). While Australian serotype 2 ST25 isolates
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could be distinguished from those of USA and Canada, only small single nucleotide polymorphism
(SNP) differences are notable across the core genome. Despite the limited number, the characterisation
of serotype 1/2 ST1 clones is significant, a finding also recently observed in North America. Indeed,
Gebhart et al. (Appendix C) characterised the diversity of a contemporary collection of S. suis isolates
across North America (mainly in USA) by serotyping and MLST to address the limited information on
current S. suis strains circulating within this country [10]. The predominant ST was ST28, followed by
ST94, ST1, and ST108 among multiple STs identified, illustrating the high diversity among S. suis isolates.
Importantly, this study revealed the predominance of serotype 1/2 ST28 from clinically affected pigs in
USA. In addition, the study also reported ST1 strains, containing the three classical virulence-associated
genes (epf, sly, and mrp), which are considered highly virulent and potentially zoonotic, an unexpected
finding based on previous epidemiological data [2]. Epidemiological surveillance of these strains in
North America is recommended [10].
S. suis is a zoonotic disease of increasing awareness. Sporadic cases of human infection have been
described worldwide since 1968; however, multiple outbreaks in some Asian countries highlight the
public health importance of this infection [2,14–16] (Appendix D). Small skin wounds are the main
route of entry in humans in Western countries, although in some cases no wound is evidenced [1].
In some Asian countries, such as Vietnam and Thailand, human S. suis is considered among the
most frequent causes of bacterial meningitis in adults [17,18]. Cultural differences between Asian
and Western countries likely impact the epidemiology of S. suis including lifestyle; common use of
backyard production systems; close contact of humans with pigs; and, in countries such as Vietnam,
Laos and Thailand, the common practice of consuming raw pork products [19–21]. It has been
clearly demonstrated that the oral route of infection is the principal cause of human infection in these
countries [1,20]. As aforementioned, serotype 2 is the main zoonotic serotype; however, serotype 14
has also been isolated from humans many times in Thailand and UK and uncommonly in France,
Australia, and Canada [1,22]. After serotype 14, serotype 5 is the third serotype most commonly found
from humans [23]. Sporadic cases due to other serotypes have also been reported [2]; among them,
serotype 9, one of the most important serotype recovered from diseased pigs in Europe, has been
recently shown to have zoonotic potential [24].
Within serotype 2, STs involved in human cases are represented in Figure 3 and parallel those
found in swine clinical cases, highlighting their epidemiological link. Kerdsin et al. (Appendix D) have
been extensively studying the epidemiological situation in Thailand [14,22]. To date, four outbreaks
of S. suis infections in humans have been recorded in that country, with case fatality rates varying
from 6.5% to 16.1%. The food safety campaign implementation in Phayao province during 2011–2013
showed a marked decrease of the disease incidence proportion and stresses the need for health policies
to reduce the burden of this infection [20]. Microbiological characterisation of S. suis in Thailand
showed that serotype 2 is the main serotype for human infections, followed by serotypes 14, 24, 5, 4, 9,
and 31. Of note, ST1 and ST104 (serotype 2) are predominant in Thai human infections. Interestingly,
the latter is almost exclusively found in that country. On the other hand, ST105 is the main ST among
serotype 14 isolates from human cases. Kerdsin et al. also revealed that Thai serotype 9 isolates are of
ST16 (Appendix D) [24], also commonly affecting pigs in some European countries [2,25]. Schultsz et
al. (Appendix E) have been studying the emergence of zoonotic S. suis infections in The Netherlands.
Zoonotic S. suis serotype 2 strains of ST20, isolated from human patients, were shown to be highly
genetically related to serotype 9 strains of ST16 [25]. It has been shown that the CPS is a major virulence
factor (see Section 3) and that the cps gene locus can be exchanged between S. suis of different serotypes.
Interestingly, a study from The Netherlands [26] showed that such CPS switch may lead to an increase
in zoonotic potential. In addition to cps locus acquisition, loss or acquisition of other genes or loci may
contribute to changes in zoonotic potential. For example, the S. suis ST20 strains (typically found in
The Netherlands) acquired not only the serotype 2 cps locus but also a type 1 Restriction-Modification
(R-M) system. Schultsz et al. (Appendix E) suggested that S. suis ST20 strains may have acquired the
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ability to adapt to specific niches through the acquisition of a R-M system that can regulate expression
of CPS and/or other (surface exposed) molecules.
Besides serotype 2 ST1 strains, which present high zoonotic potential worldwide, serotype 2
ST7 is only endemic to China, and it was responsible for human outbreaks in 1998 and 2005 in this
country [16]. In a recent study addressing the evolution of ST7 strains in China, it was shown that, of 38
sporadic ST7 S. suis strains, which mostly caused sepsis, serotype 14 was the most frequent, followed
by serotype 2. Compared to the genome of the epidemic strain (serotype 2, ST7), the major differences
in the genomes of sporadic ST7 strains were the absence of the 89 kb pathogenicity island specific
to the epidemic strain and insertion of mobile elements that play a significant role in the horizontal
transfer of antimicrobial resistance genes [27]. This is the first study addressing the evolution of the
ST7 strains and reporting serotype 14 ST7 isolates, highlighting the need to increase the surveillance of
this human life-threatening lineage of S. suis.
In addition to the “classical” described serotypes, a novel variant (serotype Chz) and strains
carrying 26 novel capsular polysaccharide loci (NCL1-26) have been identified recently [28–32]. These
findings expand the views of the genetic diversity of S. suis cps loci. Novel cps loci are continually
being found, and their discovery should eventually reduce the number of untypeable strains recovered
from diseased animals. Nevertheless, their virulence potential and the role of these NCLs in the
pathogenesis of the disease remain to be evaluated.
3. Virulence Factors and Pathogenesis of the Infection
In pigs, S. suis usually colonises the upper respiratory tract, in particular the pharyngeal and
palatine tonsils, but alimentary and genital tracts can also be colonisation sites. In fact, piglets are first
colonised by S. suis from birth as soon as they pass through the birth canal, since S. suis is found in the
sow vagina. In humans, S. suis nasopharyngeal colonisation has been reported in people working in
close contact with infected animals, such as butchers and abattoir workers [1,19,33]. The bacteria may
also colonise the gastrointestinal tract in people consuming fresh/raw contaminated pork meat [19].
Consequently, the mucosal barrier is the first line of defence of the host against this pathogen. In swine,
colonisation of the upper respiratory tract by S. suis may lead to an asymptomatic carriage but is also
considered the first step for the development of an invasive disease, particularly in the context of
coinfections with porcine respiratory viruses or polymicrobial infections [34–42].
Indeed, S. suis belongs to the “porcine respiratory disease complex”, a term used to describe a
common multifactorial respiratory disease in swine that occurs as a result of polymicrobial infections,
environmental stressors, and host factors such age and immunological status. Brockmeier et al.
(Appendix F) have been analysing the complexity of these polymicrobial infections, which can be the
result of multiple viruses, bacteria, or a combination of viruses and bacteria infecting the pig at the
same time or in close succession. For example, the majority of cases where porcine reproductive and
respiratory syndrome virus (PRRSV) or swine influenza virus (SwIV) was determined to be the primary
aetiology, also presented with secondary bacterial pneumonia caused by S. suis, among other bacterial
species. Experimental data suggest that coinfections with viruses, such as PRRSV, SwIV, porcine
circovirus, and porcine respiratory coronavirus (PRCV), generally result in a more severe clinical
disease outcome. There are several mechanisms that might contribute to increased susceptibility to
secondary infection and the enhanced disease that often occurs with coinfections, including disruption
of the epithelial barrier or alteration of the innate or adaptive immune responses by the primary
pathogen, direct interactions between or among the pathogens such as the formation of multispecies
biofilms, disturbances to the ecological niche such as the upper respiratory microbiota, or enhanced
transmission. Brockmeier et al. (Appendix F) and others [39,43–45] have shown that coinfection with
PRRSV, SwIV or PRCV and bacteria such as Bordetella bronchiseptica, S. suis or Glaesserella (Haemophilus)
parasuis results in a greater incidence of disease, greater percentage of lungs affected, more severe
lesions, and slower resolution of such lesions than occurs with infection with a single pathogen alone
and that this is often correlated with an amplified local pro-inflammatory cytokine response.
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In the absence of appropriate models of polymicrobial infections typically seen in swine production
facilities, mechanistic understanding of the underlying complex molecular and cellular interactions
remains limited. The transition between S. suis colonisation of the mucosal barriers and systemic
infection is only partially understood. In the studies performed by Wells et al. [46], a hypothetical
model to explain systemic infection of piglets with S. suis based on the identification of S. suis in
the tonsillar lymphoid tissue and presence of large numbers of CD169+ macrophages was proposed.
In this model, CD169+ macrophages might act as reservoirs for replication of virulent strains of S. suis,
whereby environmental and physical stressors that reduce competition from the tonsil microbiota
lead to increased S. suis in the tonsil and escape into the bloodstream through the many small blood
vessels permeating the lymphoid tissue. Such a model would also be compatible with the finding that
serotype 2 strains interacting with the CD169 Siglec 1 receptor through their sialylated CPS are more
commonly associated with invasive disease. Wells et al. also proposed that subversion of the innate
functions of CD169+ macrophages by coinfecting viruses such as PRRSV or SwIV may also contribute
to the survival of S. suis and spread to the bloodstream. In this context, the potential mechanisms
used by S. suis serotypes without sialic acid in their CPSs are largely unknown. It is also possible that
survival and or replication capacity of S. suis in this particular subset of macrophages is a characteristic
associated with disease-causing strains.
In this regard, research performed by Valentin-Weigand et al. (Appendix G) has significantly
contributed to our understanding of viral–bacterial interactions during airway coinfections.
One important suggested virulence factor is the S. suis cholesterol-dependent cytotoxin, named
suilysin, produced by many virulent strains. This toxin has multiple actions towards a variety of cells
(reviewed in Reference [47]), including attachment of S. suis to the surface of the respiratory epithelium
and/or direct lysis of epithelial cells [48,49], probably facilitating bacterial breach of this mucosal
barrier. However, suilysin-negative clinical isolates are also found frequently in swine populations
worldwide and especially in North America [10,50]. Valentin-Weigand et al. found that, during
secondary bacterial infection, suilysin contributes to the damage of well-differentiated respiratory
epithelial cells in the early stage of infection, whereas cytotoxic effects induced by SwIV became
prominent at later stages of infection. Besides suilysin, it has been shown that a prior infection by
SwIV enhances the adherence to and colonisation of porcine airway epithelial cells by S. suis in a
sialic-acid dependent manner and facilitates invasion in a suilysin-independent fashion [51–53]. These
findings might explain why suilysin-negative strains can also cause clinical infections (Appendix G).
As aforementioned, the potential mechanisms used by S. suis serotypes without sialic acid in their
CPSs remain to be discovered.
In humans, the intestinal route of infection seems to be an important port of entry after consumption
of fresh/raw contaminated pork meat in some Asian countries. In pigs, this route of infection has also
been investigated by direct inoculation in the intestine or oral capsule-mediated delivery of virulent
strains of S. suis into the small intestine of piglets [54,55]. In view of the inoculum size, stress-inducing
conditions, and the small proportion of challenged animals which developed invasive disease in those
studies, translocation from the intestine appears to be a possible but not a very efficient route of infection.
The conditions leading to sufficient passage of S. suis through the stomach are still unclear and might
differ in neonatal, suckling, or weaning periods. More studies are required on oro-gastrointestinal
S. suis infections in piglets to confirm the relevance of intestinal colonisation vs. infection (translocation
followed by systemic dissemination) in swine clinical cases [1]. To enlighten this controversial aspect
of S. suis disease pathogenesis, de Greeff et al. (Appendix A) studied the putative role of intestinal
colonisation for serotype 9 and showed that, during a S. suis serotype 9 outbreak, tonsils of piglets
were colonised with different serotypes. The highest percentage of colonisation was found for serotype
9, followed by serotypes 7 and 2 (Appendix A, Table A1). Similarly, serotype 9 was the major serotype
colonising the intestine (Appendix A, Table A2). The data provided by this study suggest that serotype
9 is a better coloniser of the porcine intestine than the other serotypes. Interestingly, previous in vitro
studies have shown that serotype 9 isolates can adhere to porcine intestinal cells more efficiently
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than the other serotypes [54]. Similarly, serotype 2 strains were shown to adhere better to a human
intestinal epithelial cell line than serotype 9 strains, suggesting a relationship with the high zoonotic
potential of the former serotype (Appendix E). In this in vitro model, the CPS was shown to interfere
with these first steps of S. suis colonisation and invasion, as reported in other in vitro studies with
epithelial cells [56,57]. Recent developments in stem cell research allowed intestinal organoids to
be used as infection models for S. suis. Organoids contain most cell types present in the proximal
and distal intestinal mucosa and can be dissociated and grown as monolayers on semipermeable
membranes [58,59]. A zoonotic S. suis serotype 2 strain was shown to translocate in this model, which
makes it a promising in vitro model for future study of intestinal infection with S. suis (Appendix E).
The lack of a well-standardized in vivo mucosal infection model slowed down research progress
in this area. To develop such a model, de Greeff et al. (Appendix A) applied several mucosal infection
routes to piglets from different backgrounds. It was shown that intranasal inoculation in combination
with oral inoculation result in a reproducible colonisation of the tonsils and the intestine of piglets;
however, this mild mucosal colonisation model failed to replicate clinical disease. Different stressors
facilitate and increase colonisation by S. suis but are not strict requirements for colonisation. A harsher
mucosal challenge can be achieved by combining oral inoculation with intratracheal inoculation. In this
case, the level of intestinal colonisation is lower, but more clinical symptoms like lameness, central
nervous signs, or septicaemia were induced in the piglets (Appendix A). Further optimization of the
oro-gastrointestinal infection model will definitively impact research aimed to dissect how S. suis
breaches the mucosal barriers.
Encapsulated extracellular S. suis is a highly invasive pathogen. After penetration of host mucosal
barriers, it can reach and survive in the blood and finally invades multiple organs including spleen,
liver, kidney, lung, and heart. In addition, S. suis is able to cross the brain microvascular endothelial
cells (BMECs) and/or the epithelial cells of the choroid plexus at the blood–brain barrier (BBB)
and/or the blood–cerebrospinal fluid barrier to gain access to central nervous system (CNS) [56,60,61].
Septicaemia, meningitis, endocarditis, pneumonia, and arthritis are the most common forms of S. suis
invasive disease.
The CPS of S. suis is without doubt the major virulence factor allowing this bacterium evasion
of immune-clearance mechanisms [56,62]. However, almost all of the studies on the role of CPS
used serotype 2 strains, and little is known on the role of CPSs of other serotypes as a virulence
factor. Therefore, it is unknown whether differences in serotype themselves (i.e., differences in CPS
structure/composition) directly affect S. suis virulence. To answer this question, for the first time,
Okura et al. (Appendix H) experimentally generated serotype switched mutants. Six serotype
switched mutants were generated using the serotype 2 reference strain P1/7 (P1/7cps2to3, P1/7cps2to4,
P1/7cps2to7, P1/7cps2to8, P1/7cps2to9, and P1/7cps2to14) by exchanging the CPS synthesis gene cluster
for those of serotypes 3, 4, 7, 8, 9 and 14, respectively. Their virulence was compared in mice and
pigs. Only a serotype 2 switch to CPS type 4 or to type 8 showed a marked and consistent impact
of bacterial virulence traits. The CPS8 conferred to S. suis a hyper-virulent phenotype, whereas the
CPS4 conferred to S. suis a non-virulent character. Serotype switch from CPS2 to CPS7 or to CPS3
had restricted impact, and serotype switch from CPS2 to CPS14 or to CPS9 had no significant effect
on S. suis virulence (Appendix H). Taken together, these findings suggest that serotype switching
can differentially modulate S. suis virulence depending on the CPS expressed and demonstrate its
importance on S. suis pathogenesis and clinical disease.
Based on biochemical, bioinformatics and in vitro and in vivo gene expression studies,
Ferrando et al. [63] proposed a biological model that postulates the effect of carbon catabolite repression
on expression of virulence genes in the mucosa, organs, and blood. In the oropharyngeal cavity, where
glucose is rapidly absorbed but dietary α-glucans persist, there is a profound effect of carbohydrate
availability on the expression of virulence genes. Several virulence factors involved in adherence to
host cells, degradation of connective tissue (spreading factors), and avoidance of phagocytic killing,
including suilysin, are upregulated when glucose is diminished. As discussed above, suilysin may
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facilitate dispersion of bacteria in mucosal tissues due to loss of barrier integrity. Once S. suis reaches
the bloodstream, metabolism is adapted for optimal growth on glucose and the expression of virulence
factors is reduced. In infected organs, glucose levels are lower than in the blood and are further reduced
by inflammation and utilization by S. suis, leading to upregulation of suilysin and other virulence
factors. These studies have important implications for the design of future control strategies including
the development of anti-infective strategies by modulating animal feed composition.
To further understand the genetic basis of disease in S. suis, Weinert et al. [64] studied the genomic
signatures of human and pig clinical isolates from the United Kingdom and Vietnam. Isolates associated
with disease were shown to contain substantially fewer genes than nonclinical isolates but are more
likely to encode virulence factors. Human disease isolates are limited to a single-virulent population,
originating in the 1920s, when pig production was intensified, but no reliable genomic differences
between pig and human isolates were observed, suggesting lack of consistent genomic adaptation of
S. suis to the human population. The authors also reported little geographical clustering of different
S. suis subpopulations and high rates of recombination in S. suis worldwide, implying that an increase
in virulence anywhere in the world could have a global impact over a short timescale [64].
4. Antimicrobial Resistance
S. suis infections are one of the main causes of antimicrobial usage in piglets. Indeed, the incidence
of the disease may be as high as 20%, although it is usually kept lower than 5% in the field due to the
extensive and routine prophylactic and/or metaphylactic use of antimicrobials. Data from antimicrobial
resistance of S. suis worldwide are alarming, and restriction of antimicrobials as a preventive measure
must be a primary concern [65]. In addition, the most effective drugs against S. suis are those in
categories 1 and 2 (critically or highly important). The industry is trying to reduce the use of these
drugs given their importance in human medicine. Indeed, S. suis is considered a niche for antimicrobial
resistance and represents a high risk of transmission of resistance to other pathogens [65].
Surprisingly, despite the worldwide use of beta-lactams in pigs for over 50 years, the majority of
clinical S. suis remains sensitive to these antibiotics. However, beta-lactam resistant strains do exist and
are primarily found in commensal sites (Appendix I, Figure A1). O’Dea et al. (Appendix B) reported
clinical resistance to penicillin G, albeit at a relatively low level in 8.1% of isolates. In addition, they
reported similar levels of antimicrobial resistance in Australian strains compared to those overseas
with regards to tetracycline (99.3%), erythromycin (83.8%), and trimethoprim/sulfamethoxazole (0.7%).
Resistance to florfenicol was 14.9%, while all isolates were clinically susceptible to enrofloxacin, likely
due to this being banned from use in food producing animals in Australia. Therefore, this is an aspect
of S. suis in Australia that must be carefully monitored from both an animal and public health point
of view.
In a recent work, Libante et al. [66] made a comprehensive in silico search and analysis of
Integrative Conjugative Elements (ICEs) and Integrative and Mobilizable Elements (IMEs) and
extensive identification of antimicrobial resistance genes present in 214 S. suis draft genomes. Almost
400 antimicrobial resistance genes were detected in the 214 genomes analysed. A huge amount of ICEs,
IMEs, and derived elements were detected at various chromosomal sites. High diversity was observed
in recombination but also in conjugation/mobilization modules. Besides ICEs, IMEs appear to be major
vehicles of antimicrobial resistance genes. The authors concluded that further studies are needed to
evaluate such gene fluxes inside and between ecosystems and the contribution of ICEs and IMEs in
these gene transfers keeping in mind a one health global perspective.
5. Prevention and Control of S. suis Diseases
As S. suis is a very early coloniser of piglets, it cannot be eliminated by early weaning [1]. To reduce
antimicrobial use, S. suis disease prevention should concentrate on management of predisposing
factors and, mainly, vaccination. Despite intensive research leading to different vaccine-candidate
antigens [67], no universally efficacious S. suis vaccine has been commercialised so far. The dream of
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having a universal cross-protective vaccine is highly challenging due to the high genomic diversity
of S. suis. As discussed in the work performed by Weinert et al. (Appendix I), considerable genetic
diversity of S. suis exists. Nonetheless, they have shown many trends in genetic and phenotypic
differences between strains isolated from the upper respiratory tract of pigs without S. suis clinical
signs (referred as “nonclinical”) and strains isolated from the lungs or systemic sites of pigs with S. suis
clinical signs (referred as “clinical”) (Appendix I, Figure A1). Overall, the genetic diversity of clinical
S. suis is less than that of nonclinical strains, implying that a design of a universal vaccine to control
S. suis clinical infection might be possible.
Over 38 subunit vaccine candidates have been reported [67,68] and new ones are continuously
being characterised, yet homologous protection is still controversial and cross-protection (either against
other serotypes or at least using heterologous strains) was evaluated in few of these studies [69–75].
Lack of well-standardized animal models for immunization and challenge, especially for serotypes
other than 2, is one of the reasons of limited progress towards a subunit vaccine, which also results in
contradictory results for a same vaccine candidate [67]. Amongst other confounding factors are the use
of mouse models (for pre-screening) without confirmation in swine trials, number of vaccine doses,
and different adjuvants (which are not always compatible with a future use in swine medicine). More
research, with better standardized protocols, would certainly advance subunit vaccine development.
One common vaccine target is, without doubt, the CPS because the majority of clinical strains
have a capsule (Appendix I, Figure A1). Nevertheless, the vaccine-induced protection will be
serotype-restricted. Multiple different polysaccharide epitopes should be selected in a vaccine to target
different serotypes, and vaccination-driven strain replacement of the population might be expected.
Finally, in addition to their diversity and as aforementioned, cps loci are often recombination “hot-spots”
and this gives rise to CPS “switching” between strains. Highly conserved proteins might help overcome
these limitations and fight strain replacement/evolution. As S. suis is part of the commensal flora, any
preventive/control strategy should eliminate clinical isolates without altering the precious balance
of the pig mucosal microbiota. Albeit possible disease-protective limitations, a systemic vaccination
approach is to be prioritized in this context (Appendix I).
Due to the young age of the piglets affected and the lack of an effective commercial vaccine
(as discussed above), many farms use metaphylactic perinatal antimicrobials to control S. suis disease.
Besides the public health concern related to antimicrobial use in production animals and the increase
in antimicrobial resistance, an additional problem of antimicrobial usage is that these treatments
can also affect the beneficial bacteria of the microbiota. In an attempt to understand the harmful
effect of overuse of antimicrobials at early age, Aragon et al. (Appendix J) have evaluated the
outcome of perinatal antimicrobial treatment on the nasal microbiota at weaning. Elimination of
perinatal antimicrobials resulted in an increase in bacterial diversity in the nasal microbiota at weaning.
Furthermore, management of lactation without perinatal antimicrobials had a beneficial impact later in
life in terms of animal health and productivity in the nursery phase. Albeit more detailed studies are
required, Aragon et al. also observed that perinatal ceftiofur administration might favour colonisation
with potentially clinically relevant serotypes of S. suis. As such, the precise effects of antimicrobial
metaphylaxis are difficult to predict (Appendix J).
The only available vaccines used in the field are autogenous, which consist of killed bacteria
(“bacterin”) from the predominant strain(s) recovered in an affected farm, produced by licenced
laboratories and given back to the same farm only. However, there are very few scientific studies
demonstrating whether the use of such vaccines in the field correlates with a reduced mortality and
curative antimicrobial use. Indeed, field peer-reviewed reports on autogenous vaccines are almost
nonexistent (only 2 published papers in the last 30 years) [76,77]; others are incomplete and, in
most of them, a control (non-vaccinated) group is missing, which may preclude any scientifically
sound conclusions [68]. On the other hand, controlled experimental (laboratory) studies have
shown contradictory results concerning bacterin-induced protection [67,68]. That controversial
protective response could be attributed, among others, to a loss of antigenicity caused by the killing
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procedure and/or production of antibodies against antigens not associated with protection. Moreover,
autogenous vaccines are “manufacturer-related” (each licenced laboratory uses different protocols,
antigen concentration, adjuvants, etc.) and “farm-specific” (useful against homologous—same
strain—challenge only) [67]. Finally, the correct diagnosis of S. suis as a primary cause of disease
may complicate the choice of the strain(s) to be included in the autogenous vaccine. There is still an
unresolved issue concerning isolates recovered from lungs, which are considered by many researchers
as secondary invaders and may or may not (depending on the laboratory) be included in the vaccine
as antigens. Definitively, more studies are required to generate scientific knowledge to improve this
important preventive tool and to help reduce the use of antimicrobials.
6. Policy on Autogenous Vaccine Manufacturing
The wide use of autogenous vaccines and cross-border movement of animals vaccinated with
autogenous vaccines is now a common practice within Europe. Therefore, harmonising quality of
these products has been considered necessary by the Coordination Group for Mutual Recognition and
Decentralised Procedure—Veterinary (CMDv) and the national competent authorities for Veterinary
Medicinal Products (VMPs) in Europe. M. Saléry discussed in Appendix K the regulatory framework
of the manufacture, control, and use of autogenous vaccines within the European Union. Recently, a
new legislation on VMPs has been adopted in European Union, applicable in January 2022. In this
new regulation, autogenous vaccines have an updated definition and fall under European regimen.
Article 2(3) of this regulation requires that some articles of the regulation apply to “inactivated VMP
manufactured from pathogens and antigens obtained from an animal or animals in an epidemiological
unit and used for the treatment of that animal or those animals in the same epidemiological unit
or for the treatment of an animal or animals in a unit having a confirmed epidemiological link”.
The introduction of the concept of epidemiological link allows now the use of autogenous vaccines in
parental lines or for animals prior their introduction in fattening sites where they will be in contact with
new pathogens. In addition, different laboratories working under different conditions presently exist in
Europe. From January 2022, all autogenous vaccines will have to be done under Good Manufacturing
Practices (GMP) or GMP-like requirements. The manufacturers will have to be authorized, and the
compliance with the requirements will be controlled by inspection. As a consequence, autogenous
vaccines will be produced under similar quality conditions. However, among others, differences
in antigen preparation, antigen concentration, method of killing, and type and concentration of
the adjuvants will still exist. In Appendix K, M. Saléry summarized key points from the CMDv’
recommendation paper [78], which deals with the manufacture, the control, and the use of viral
and bacterial autogenous vaccines in Europe. In the framework of the new regulation, the CMDv’
recommendations will be updated in the coming years. The current and future regulatory framework
ensures those products are of high quality. Nevertheless, safety and efficacy are not regulated. Safety
and, more importantly, efficacy of S. suis autogenous vaccines need to be better demonstrated through
field use and laboratory research.
7. Conclusions
Intensification of animal food production and emergence of new production systems (such as
raised without antibiotics or organic systems as well as “Humane” animal farming) has resulted
in emergence or reemergence of pathogens. In this context, coinfections are more likely to occur,
increasing the incidence and/or enhancing clinical disease with certain pathogens, including S. suis.
Continued development of suitable models for polymicrobial infections and a better understanding of
the underlying pathological mechanisms are required to develop effective intervention strategies to
prevent the effects of these diseases on swine production.
Mucosal infection models still require optimization and have the potential to improve our
knowledge of the pathogenesis of S. suis-induced disease. These models would significantly contribute
to vaccine development as well. Research on mucosal infection and immunity will also help address
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the potential use of nutrition management and/or microbiota enhancement to improve swine health
and, consequently, S. suis control strategies. Early medication with antimicrobials has to be carefully
considered since antimicrobials may interfere with the establishment of the microbiota and, in
consequence, with immune maturation and other microbiota functions, which may have a lasting
health effect later in life.
S. suis importance as a zoonotic pathogen is continuously increasing due to, at least in part, the
pressure to reduce antimicrobial use in livestock. This public health threat is enhanced by the lack
of universally effective vaccines that might reduce the infection load in swine and thus the risk for
humans. Global strengthening of swine trade amongst countries has the potential to facilitate exchange
of genetic material through recombination and mobile genetic elements, which may result in selective
advantage and niche adaptation. It is crucial to understand the factors that are involved in the ability
to cause zoonotic infection and to monitor if these may eventually result in S. suis strains that are more
human adapted.
Indeed, a better worldwide surveillance system of S. suis-related disease in swine and humans
would improve our understanding of the epidemiological evolution of this pathogen. New molecular
tools have been developed; however, due to the diversity of S. suis and lack of appropriate
markers to differentiate virulent strains from commensal ones, alternative techniques might still
be required to achieve a comprehensive understanding of the S. suis bacterial community, including
virulence-associated gene profiling. The development of such tools that might eventually allow
prediction of virulence potential of a strain might be compromised by sampling strategies and the rich
S. suis community in the upper respiratory tract of healthy animals.
In the era of antimicrobial restrictions and new social meat consumption trends, improvement
and/or development of vaccination strategies is of utmost importance. In spite of decades of research
on S. suis vaccines, autogenous bacterins are the only control strategy available that swine producers
have access to. Due to intensive use of these vaccines in Europe, new policies are in place that would
improve and normalize their manufacturing. The implantation of similar policies worldwide, including
North America, where the use of autogenous vaccines is also widespread, would be expected or sought
after. Nevertheless, more field studies are essential to scientifically validate their protective effect and,
consequently, their cost–benefit impact for swine producers.
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Proceeding from the 4th International Workshop on Streptococcus suis
Streptocccus suis serotype 9 infection: Novel animal models and diagnostic tools
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A.1. Serotype 9 is the dominant serotype in Western Europe
Streptococcus suis is a highly diverse organism; currently 29 serotypes have been described [6,29].
Historically, serotype 2 was the predominant serotype causing infections in piglets worldwide. However,
recently, a shift towards serotype 9 has occurred, in particular in Western Europe [2]. In recent years,
however, incidence of serotype 9 infections in pigs increased in South East Asia [79] and to a lesser
extent in North America [80]. In Thailand, serotype 9 was isolated from a human patient with severe
disease symptoms [24], emphasizing the zoonotic potential of serotype 9 isolates, that was already
suggested [26].
In The Netherlands, all farms are colonised by serotype 9. Colonisation with S. suis serotype 9
is not directly correlated with S. suis disease. Obviously, additional risk factors are determinative in
causing disease. Unfortunately, autovaccination against serotype 9 is less effective than against serotype
2, making it difficult to combat the infection [81,82]. Under experimental conditions, S. suis serotype 9
is hardly virulent [83], whereas in practice, many piglets develop severe invasive disease after S. suis
serotype 9 infection. There could be different explanations for this discrepancy. First of all, additional
risk factors occurring under field conditions may play a role in disease development like existing viral
or bacterial coinfections, management factors, or housing conditions. Alternatively, serotype 9 isolates
in the field might differ in virulence from the isolates used in experimental infections. It has been
described that the S. suis serotype 9 population is genetically very diverse [10,64,79,84]. In addition, it
has been described that differences in virulence exist within the serotype 9 population [79], similar to
that described for serotype 2 [85].
Taken together, S. suis serotype 9 has been emerging for the last decade and is spreading around
the world. Due to the large genetic and phenotypic heterogeneity in the serotype 9 population, it is a
complex pathogen to study.
A.2. Population genetics of S. suis serotype 9
To get more insight in the genetic population of S. suis serotype 9 in The Netherlands, an
epidemiological study was performed [8]. Two populations of serotype 9 isolates were included for
genotyping analysis: clinical isolates and isolates from healthy carrier piglets. Seventy-eight isolates
from clinical cases of S. suis were included in the study and were isolated from the CNS of animals
with invasive S. suis disease (meningitis). The isolates from healthy carrier pigs were isolated from 6
independent farms that did not have clinical outbreaks caused by S. suis for at least two years (n = 50).
Tonsils of healthy sows and piglets were sampled, and S. suis serotype 9 isolates were isolated after
plating. Genotyping of the isolates using Comparative Genome Hybridization (CGH) revealed that
the two populations were genetically very distinct. CGH split the population in two clusters: one
cluster only contained carriage isolates, whereas the other cluster contained all clinical isolates plus a
few carriage isolates. These carriage isolates probably reflect clinical isolates that are not causing any
clinical outbreaks on the farms but do have virulent potential.
To further analyse the genetic differences between the isolates, all serotype 9 isolates were subjected
to whole genome sequencing. A systematic analysis of the data showed that the clinical isolates
clustered mainly together in one group whereas the carriage isolates were distributed across 8 different
groups. This suggested that virulent serotype 9 isolates are genetically very similar, whereas the
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carriage isolates are more heterogeneous [8], as was described before [10,64,79,84]. Based on our data,
the heterogeneity was only found for the carriage isolates.
Our data suggest that at least two virulence phenotypes of serotype 9 isolates exist: clinical
isolates that are virulent and avirulent carriage isolates. To confirm there are differences in virulence
among serotype 9 isolates, four isolates were tested for virulence under experimental conditions.
Two carrier isolates, one clinical isolate, and one laboratory strain that clustered among the clinical
isolates were tested for virulence by infecting CDCD piglets intravenously with a high dose of each of
the isolates. The survival curves clearly showed there was a significant difference in virulence between
carriage isolates and clinical isolates. Although the carriage isolates could induce S. suis specific disease
symptoms like lameness, 80%–90% of the piglets survived the infection, whereas the piglets infected
with the clinical isolates all died within 2 days postinfection. In conclusion, it was shown that, within
S. suis serotype 9, the virulence of clinical isolates and tonsillar carriage isolates differed significantly.
A.3. Intestinal translocation
Due to the zoonotic S. suis outbreaks in South East Asia, a lot of attention has been paid to putative
risk factors for human S. suis infections [19,86]. One of the risk factors that has been identified is
occupational exposure, which is the main risk factor for human infections in the Western world as
well [87,88]. However, a new risk factor that was identified due to the outbreak in Asia is consumption
of raw or undercooked pig products like raw blood soup. By ingesting contaminated pork products,
S. suis infections can occur. This insight directed research into the role of intestinal translocation in
porcine S. suis infections.
It is known that S. suis colonises the gastrointestinal tract of piglets in high numbers, in particular
after weaning [89]. In addition, under experimental conditions, invasive S. suis serotype 2 infections
could be induced by intestinal inoculation of piglets [55]. To study the putative role of intestinal
colonisation for serotype 9, an epidemiological study was performed at the Wageningen University
and Research experimental farm in Sterksel, The Netherlands. It was shown that, during a S. suis
serotype 9 outbreak, tonsils of piglets were colonised with different serotypes. The highest percentage
of colonisation was found for serotype 9, followed by serotype 7 and 2 (Table A1). Only a few animals
were colonised by serotype 1.
Subsequently, colonisation in S. suis specific organs and the intestine was studied in 20 S. suis
diseased animals and 20 healthy litter mates. It was shown that specific organs were exclusively
colonised by serotype 9, as was expected since there was a serotype 9 disease outbreak on the farm.
However, up to 85% of the healthy controls and 95% of the diseased piglets were also colonised by
serotype 9 in the intestine, whereas the other serotypes did not colonise at all in the intestine or only in
a limited number of animals (Table A2). Faecal samples were also screened for presence of serotypes 1,
2, 7, and 9. Whereas none of the piglets were positive for serotypes 1 or 2, a few animals were positive
for serotype 7 and a considerable number of animals were positive for serotype 9 in faeces.
Table A1. Presence of S. suis serotypes 1, 2, 7, and 9 in tonsils and faecal samples of piglets at Sterksel
farm as determined using qPCR.
Sample Time Point S. suis 1 S. suis 2 S. suis 7 S. suis 9
Tonsil
1 day preweaning 10/132 (8%) 7/132 (5%) 43/132 (33%) 113/132 (86%)
1 week postweaning 2/130 (2%) 10/130 (8%) 80/130 (62%) 124/130 (95%)
4 weeks postweaning 3/109 (3%) 19/109 (17%) 80/109 (73%) 105/109 (96%)
Feces
1 day preweaning 0/132 (0%) 0/132 (0%) 1/132 (1%) 45/132 (34%)
1 week postweaning 0/130 (0%) 0/130 (0%) 3/130 (2%) 31/130 (24%)
4 weeks postweaning 0/109 (0%) 2/109 (0%) 0/109 (0%) 11/109 (10%)
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Table A2. Presence of S. suis serotypes 1, 2, 7, and 9 in specific organs (joints and central nervous
system (CNS)) and intestinal samples of piglets at Sterksel farm as determined using qPCR.
Sample Status S. suis 1 S. suis 2 S. suis 7 S. suis 9
Joints/CNS
Diseased 0/20 (0%) 0/20 (0%) 0/20 (0%) 16/20 (80%)
Healthy controls 0/20 (0%) 0/20 (0%) 0/20 (0%) 0/20 (0%)
Intestine
Diseased 0/20 (0%) 0/20 (0%) 5/20 (25%) 19/20 (95%)
Healthy controls 0/20 (0%) 1/20 (5%) 5/20 (25%) 17/20 (85%)
Although only one farm was sampled in this study, the data suggest that serotype 9 is a better
coloniser of the porcine intestine than the other serotypes. This suggestion was supported by the data
published by Ferrando et al. [54] that showed that serotype 9 isolates can adhere to porcine intestinal
cells more efficiently that the other serotypes. Furthermore, it was shown that translocation of S. suis
serotype 2 via the intestine can cause severe invasive disease in piglets.
A.4. Mucosal infection model
The putative role of the intestine in invasive translocation of S. suis opens up new possibilities
in the prevention of S. suis disease. If the intestine plays an important role in the pathogenesis of
disease, feed interventions might contribute to prevention of disease. Feed components can either
strengthen the intestinal barrier thus preventing translocation, they can exhibit antimicrobial effects
and kill S. suis, or they can affect microbiota composition in such a way that S. suis cannot colonise
anymore (competitive exclusion). To evaluate the effect of this kind of interventions, an experimental
mucosal infection model is required. At the moment, only an intravenous model is available that leads
to severe invasive disease symptoms. A more subtle infection model following mucosal challenge
route would be very interesting.
To develop such a model, several mucosal infection routes were applied to piglets from a different
background. It was shown that intranasal inoculation in combination with oral inoculation will result
in a reproducible colonisation of the tonsils and the intestine of piglets, even when they are endemically
colonised by serotype 9. To mimic the weaning stress piglets experience under field conditions,
several stressors were applied to the piglets, like transport stress, social stress (no acclimatization), or
pretreatment of the nasal mucosa with acetic acid. These stressors facilitate and increase colonisation
by S. suis but are a not strict requirement for colonisation. This mild mucosal colonisation model does
not lead to clinical disease. A harsher mucosal challenge can be achieved by combining oral inoculation
with intratracheal inoculation. In this case, the level of intestinal colonisation is lower, but more clinical
symptoms like lameness, central nervous signs, or septicaemia were induced in the piglets.
Before applying any of those models, some critical parameters need to be determined. First of all,
the background of the piglets is of utmost importance for the outcome of the experiment. Piglets from
the field with maternal antibodies and a natural exposure to endemic pathogens are more resilient to
experimental S. suis infection. This is particularly true for animals from farms with a relative high
hygiene standard and good management practices. Piglets from high health farms with a specific
pathogen free status are more susceptible to infection. CDCD piglets are very sensitive to all infections
due to their complete naive immune system. Another important parameter is the application of
a stressor. Especially when more resilient piglets are used, a stressor is very helpful to increase
susceptibility to colonisation and disease. Several stressors can be used; in our studies, social stress,
transport stress, and acid exposure were applied.
A.5. Conclusions
In conclusion, it was shown that S. suis serotype 9 is a very heterogeneous pathogen that has at
least two pathotypes. Carriage isolates are very diverse and have a low virulence, whereas clinical
isolates are genetically less diverse and more virulent (though they are less virulent than MRP+EF+
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serotype 2 isolates). New pig models were developed for experimental colonisation and disease caused
by S. suis serotype 9. These models can be used for intervention studies aiming to reduce colonisation
or disease caused by S. suis serotype 9. There are strong indications that intestinal colonisation plays
an important role, in particular, for serotype 9 infections. More research is required to study this porte
d’entrée in more detail.
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Information relating to Streptococcus suis in the Australian pig herd is limited [11,12]. Given the
paucity of data available on S. suis associated with disease in Australian pigs, the aim of this study was
to analyse and characterise a significant number of S. suis isolates from diseased pigs obtained across
multiple production sites and spanning a seven-year period.
A total of 148 swabs from archived clinical isolates spanning the years 2010 to 2017 were subjected
to antimicrobial susceptibility testing via broth microdilution; whole genome sequencing via Illumina
Nextseq; and detailed genomic interrogation for presence of antimicrobial resistance elements, putative
virulence genes, serotype, and MLST. In addition, core genome phylogenetic analysis of Australian
isolates and 383 previously published international isolates was performed.
Genomic analysis of the 148 isolates revealed that 110 isolates belonged to 11 previously identified
MLSTs, with 38 isolates belonging to one of 26 newly identified MLSTs. The most prominent MLSTs
were ST 27 (27/148), ST 25 (26/148), ST 28 (11/148), ST 483 (11/148), and ST 1 (10/148).
Analysis of the capsular genes resulted in two major serotypes being detected: serotype 2 (39/148)
and serotype 3 (37/148). The other main serotypes were 1/2 (11/148), 16 (8/148), 19 (8/148), 8 (7/148),
and 4 (7/148). Analysis of serotype and MLST combinations showed a high proportion of isolates as
serotype 2 ST25 (17.6%), serotype 3 ST27 (18.2%), and serotype 2 ST28 (6.1%).
The proportions of isolates carrying the main virulence factors mrp, epf, or sly across all isolates
were 7.4% (cps 1/2, 2, 14, and 19), 6.8% (cps 1/2, 2, and 14), and 33.1% (cps 1/2, 2, 3, 4, 5, 7, 8, 11, 12, 14,
15, 16, 18, 19, 21, and 23), respectively. Only a single isolate carried both mrp and sly, while 6.8% of
isolates carried both mrp and epf and 6.8% carried mrp, epf, and sly. The isolates carrying all three
genes belonged to serotypes 1/2 (n = 7), 2 (n = 2), and 14, and all belonged to ST1, with a significant
association between ST1 and the carriage of all three genes (Fisher’s exact test p-value < 0.0001).
Detailed examination of the virulence gene profiles demonstrated that the Australian isolates
could be grouped in multiple clades based on putative virulence gene carriage. Of most significance
was a single clade containing a conserved block of 32 putative virulence genes, which was the only
group to contain the genes dppIV, epf, mrp, sbp2, oppA, and lde. This group consisted predominantly of
serotype 1/2 and serotype 2 isolates, and all were ST1.
On average, the total gene content of systemic isolates from brain and joint was 2057, significantly
lower than that from respiratory isolates which carried 2109 (Mann–Whitney U test p-value = 0.025).
When the total gene content of isolates was compared to the number of putative virulence genes, a
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trend was observed based upon ST. This was most apparent in the ST1 isolates which had a significantly
higher number of putative virulence genes compared to the other STs and the lowest average total
gene content of 1918 (p-value < 0.00001).
Phylogenetic comparison of the S. suis strains isolated from Australian pigs against a global
collection of S. suis strains resulted in the identification of four major clades. The strains from this
study were present in all four clades. The majority of the Australian strains (89/148) clustered in clade
2, which was comprised entirely of strains from the UK, North America, and Canada. Only eight
strains were present in clade 4, which was made up of Vietnamese and UK isolates. While Australian
serotype 2 ST25 isolates could be distinguished from North America and Canadian strains, the small
SNP difference was notable; as aside from a single isolate, Canadian and Australian isolates differed by
a maximum of only 100 SNPs across the core genome.
A high proportion of the isolates were resistant to both tetracycline (99.3%) and erythromycin
(83.8%). Low levels of resistance were observed for florfenicol (14.9%), penicillin G (8.1%), ampicillin
(0.7%), and trimethoprim/ sulphamethoxazole (0.7%). None of the isolates were resistant to enrofloxacin.
In this study, we present the key findings of the virulence potential of ST1 clones and the
limited evolution of Australian clones from their global seed strains. In terms of virulence genes, the
mrp+/epf+/sly+ combination was carried by all ST1 isolates, and these were consistently the isolates
with the largest array of putative virulence factors. In addition, a conserved constellation of virulence
genes, a number of which are associated with adhesion and which were not present in other MLSTs,
provides some insight into the virulence of ST1 clones. When this gene block was investigated in ST1
clones from overseas, it was also found to be highly conserved across 226 isolates. Taken together, these
factors suggest that both Australian and international ST1 clones have a distinct fitness advantage
in terms of binding ability towards host target cells, and ST1 bacterial adhesion factors may be a
promising vaccine target.
Antimicrobial resistance of Australian strains was similar to levels reported overseas with regards
to tetracycline (99.3%), erythromycin (83.8%), and trimethoprim/sulfamethoxazole (0.7%). Resistance
to florfenicol was 14.9%, while all isolates were clinically susceptible to enrofloxacin, likely due to this
being banned from use in food producing animals in Australia. Of concern was the observed clinical
resistance to penicillin G, albeit at a relatively low level in 8.1% of isolates. Therefore, this is an aspect
of S. suis in Australia that must be carefully monitored from both an animal and public health point
of view.
In conclusion, our findings demonstrate that Australian clones of S. suis associated with clinical
disease in pigs have maintained a stable core genome, mirroring the international seed-stock from
which they were derived. Australian clones associated with disease in pigs consist predominantly of
serotypes 2, 3, and 1/2, which is consistent with reports from other pig producing countries [2]. Despite
the limited number, the characterisation of serotype 1/2 ST1 clones is significant, as all displayed
distinctive factors associated with highly virulent S. suis.
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Streptococcus suis, an increasingly important pathogen of swine in the United States of America
(USA), is composed of both pathogenic and commensal strains. Commensal strains normally reside
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in the upper respiratory tract of pigs, and pathogenic S. suis strains are associated with meningitis,
arthritis, endocarditis/epicarditis, polyserositis, and septicaemia in piglets and growing pigs [1,90].
Identifying major disease-causing strains can promote the development of treatment and control plans.
MLST is a widely used method for subtyping strains, but information on the subtype distribution
of S. suis strains in the USA is limited or outdated. A 1992 study investigated the serotype distribution
of porcine S. suis strains in Minnesota and reported the prevalence of serotypes 2–9 and 11, of which
serotype 2 was the predominant serotype associated with neurological disease [91]. A 1993 study
identified serotypes 1–8 and 1/2 in naturally infected pigs, with serotype 2 being the predominant
serotype in USA [92]. A large USA study in 2009 investigated the serotype distribution of S. suis strains
collected from 2003 to 2005 from 17 states. This 2009 study illustrated that the distribution of strains
was similar to that in Canada in which serotypes 1/2, 2, 3, 7, and 8 were most prevalent in diseased
pigs [93,94] and dissimilar to the distribution in Europe in which serotype 2 occurs at a considerably
higher percentage of isolates than in North America [95]. On the other hand, studies addressing MLST
for S. suis largely focus on common STs of serotype 2. ST25 and ST28 are more common among strains
recovered from diseased animals in North America, while ST1 strains are more prevalent in Europe
and Asia [25,83,96].
The objective of this study was to characterise the diversity of 208 S. suis isolates collected between
2014 to 2017 across North America (mainly the USA) by serotyping and MLST to address the limited
information on current S. suis strains circulating within the USA [10]. Isolates were also characterised
by pathotype, based on clinical information and site of isolation, as pathogenic (from neurologic or
systemic tissues, n = 139), possibly opportunistic (from lung samples, n = 47), or commensal (from
healthy pigs, n = 22). The subtype distributions were further analysed by pathotype to determine
prevalent subtypes recovered from diseased pigs.
Serotyping identified 20 different serotypes and the predominant serotypes were 1/2 (n = 54)
and 7 (n = 23). Fifty-eight different STs were identified and 38 were newly identified STs (961–969,
971–998, and 1001; n = 56). The predominant ST was ST28 (n = 52), followed by ST94 (n = 18), ST1, and
ST108 (n = 17 each). Fifteen of the 20 serotypes identified contained multiple STs, with the number of
different STs within a single serotype ranging from 2 to 8. The subdivision of S. suis serotypes by ST
further illustrated the high diversity among the isolates. Furthermore, the isolates were selected from
20 different states, representing the major swine producing states in the USA. Geographic distribution
of the S. suis serotypes in our study identified serotype 1/2 in 13 of the 20 states, with a concentration
in five.
We investigated associations between subtype (serotype and MLST) and pathotype classifications
using odds ratio (OR) and phylogenetic analyses. Between 80%–100% of isolates belonging to serotypes
1, 1/2, 2, 7, 14, and 23 were classified as the pathogenic pathotype, and these associations were supported
by OR analysis. Twelve STs, including STs 1, 28, 94, and 108, contained over 75% of isolates classified
as pathogenic, which demonstrated the same associations by OR. Interestingly, many of the novel STs
that occurred as singletons were identified as the commensal pathotype. Commensal isolates are not
generally subjected to subtyping by MLST, which may explain the large number of novel STs.
To investigate genetic relationships among the samples and possible associations among serotype,
genotype, and pathotype classifications, the MLST allelic sequences were clustered. MLST clustering
analysis demonstrated three clades with an association to pathotype. The first clade represents mostly
the pathogenic pathotype and includes largely serotype 1 (with some serotype 2 and 14) and ST1
isolates. The second clade represents mostly the pathogenic pathotype and contains serotype 1/2 and
ST28 isolates, the predominant subtypes in our USA sample set. The third clade represents mostly the
commensal pathotype and a variety of serotypes and STs (most of them novel STs).
These results demonstrated the use of serotyping and MLST to differentiate pathogenic from
commensal isolates and to establish links between pathotype and subtype, thus increasing the
knowledge on S. suis strains circulating in the USA. However, due to the diversity of S. suis, alternative
subtyping techniques should be explored to consistently differentiate pathogenic from commensal
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strains. Alternative subtyping techniques include virulence-associated gene (VAG) profiling of S. suis.
Identification of the virulence factors of S. suis has been previously explored for understanding
the pathogenesis of S. suis infection, and there are currently over 100 putative virulence factors
reported [3,56,84,97]. However, information on the distribution of these factors in USA isolates
is limited.
We characterised the same set of 208 isolates by VAG profiling to investigate the distribution
of the 66 VAGs in USA isolates. Presence/absence of these 66 VAGs was used to perform clustering
analysis, which also demonstrated three clades with an association to pathotype; these clades were
further investigated by serotype and ST. The first clade represents the pathogenic pathotype containing
serotypes 1 and 2 and ST1, consistent with publications associating ST1 with high virulence [96,97].
The second clade largely represents the pathogenic pathotype and contains isolates subtyped as
serotype 1/2 and ST28. The third clade contains isolates of the commensal and possibly opportunistic
pathotypes belonging to numerous serotypes and STs. The three classical VAGs of S. suis serotype 2
strains (epf, sly, and mrp) were found in the ST1 clade but not in the ST28 clade. Several other VAGs
were identified that may potentially differentiate the pathogenic from the commensal pathotypes and
may be better predictors of pathogenicity for USA strains.
In this study, 208 S. suis isolates from North America were characterised by serotyping, MLST,
and VAG profiling. These findings will contribute to the knowledge on the population structure of
S. suis strains currently circulating in the USA. We demonstrated the use of serotyping and MLST for
the subtyping of strains and for investigating associations between subtypes and pathotype to identify
pathogenic strains. The identification of pathogenic strains is important for enhancing strain selection
for preventive strategies. The subtype distributions in our study elucidated the predominance of
serotype 1/2 ST28 and ST1 isolates from clinically affected pigs in the USA, which may inform new
diagnostic approaches and virulence studies. We also determined the diversity of the isolates by MLST
and VAG clustering analyses, both of which illustrated one commensal and two pathogenic clades [10].
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In Thailand, S. suis infection was first described in 1987, with 2 cases of meningitis [98]. Since
the largest outbreak of human S. suis infection occurred in Sichuan province, China in 2005 [16],
the importance of this disease has been increasingly recognized in Thailand. Up to the present,
4 outbreaks of S. suis infections in humans have been recorded in Thailand. The first outbreak
including 29 laboratory confirmed cases and 3 deaths, occurring in Phayao Province during May
of 2007 [99]. A second outbreak was recognized in Chiang Mai and Lamphoon provinces during
June–July, 2008, including 44 confirmed cases, 26 suspected cases, and 3 fatal cases with septic shock
(http://www.boe.moph.go.th/Annual/Annual%202552/WESR2552/wk52_38/wk52_38.pdf). The third
outbreak was found in Phetchabul province in April, 2010; this outbreak had 14 confirmed cases with 5
fatal (http://www.boe.moph.go.th/Annual/aesr2553/wesr_2553/wk53_17.pdf). The fourth outbreak has
been reported in Uttaradit province in May, 2019 with 14 cases (https://ddc.moph.go.th/uploads/files/
67f5dfba9522d8862ca862d9c43a5a66.pdf).
Consequently, a total of 2011 cases and 131 fatal cases of S. suis infection in Thailand have
been reported by the Bureau of Epidemiology, Ministry of Public Health since 2013–August, 2019
(http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=situation&ds=82). Of note, case
fatality rate was 6.5% in contrast with 2 retrospective studies that revealed case fatality rates of 9.5% and
12.7%, respectively [100,101]. However, a prospective study demonstrated a case fatality rate of 16.1%
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and an incidence rate of 6.2 per 100,000 in the general population. The main route of S. suis infection in
Thailand was consumption of traditional raw pork or pig’s blood products [15,99–101]. Food safety
campaign implementation in Phayao province during 2011–2013 showed a marked decrease of the
incidence proportion [20]. The annual incidence proportion significantly decreased from 6.4/100,000
persons in 2010 (before implementation) to 2.7/100,000 persons in 2011, to 2.0/100,000 persons in 2012,
and to 3.5/100,000 persons in 2013. This revealed a 3.94/100,000 persons decrease in the trend of
incidence proportion after campaign (p < 0.001) [20].
Microbiological characterisation of S. suis in Thailand showed that serotype 2 (93.4%) was the
main serotype in human infections in Thailand, followed by serotype 14 (5.2%), 24 (0.6%), 5 (0.4%), 4
(0.1%), 9 (0.1%), and 31 (0.1%), respectively [14,22,24,100–103]. MLST classified serotype 2 into 5 clonal
complexes (CC) that were CC1, CC25, CC28, CC104, and CC233/379. While serotype 14 was classified
to only CC1 by MLST, ST1 was the major ST of serotype 2 found in CC1, whereas ST105 was the main
ST in CC1 of serotype 14. ST104, ST25, ST28, and ST233 were the main STs in CC104, CC25, CC28,
and CC233/379 of serotype 2 [14,22,100,101]. Of note, ST1 and 104 (serotype 2) are predominant STs in
Thai human infections. In contrast, serotypes 24 and 31 and some isolates of serotype 5 were classified
in CC221/234, with the majority belonging to ST221. It is also interesting that CC104, CC233/379,
and CC221/234 are exclusively found in Thailand only. MLST determined that the Thai serotype
9 isolates were of ST16, which belongs to clonal complex 16 [24]. Serotype 9 is the most common
serotype affecting pigs in European countries, especially ST16 which is found in ≥89% of cases in The
Netherlands [2,25].
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Streptococcus suis is an emerging zoonotic pathogen. Although many countries perform systematic
surveillance of vaccine-preventable and other common causes of meningitis, S. suis meningitis is not
a notifiable disease, with the exception of northern Thailand between 2008 and 2012. The burden
of human S. suis infections is likely to be underestimated as indicated by case reports from an
increasing number of countries [2,104–109], and human S. suis infections have now been reported
from all continents. A recent study estimated the burden of disease caused by S. suis in Vietnam and
reported annual disease incidence ranging from 0.249 to 0.324 per 100,000 population, in the years
2011–2014 [110]. Risk factors for human infection include consumption of raw pork blood or products;
direct exposure to pigs, particularly in the presence of skin lesions; pig related occupations; and male
sex [19,86,87]. Human-to-human transmission has not been demonstrated to occur to date.
S. suis serotype 2 is the main serotype causing zoonotic infections. Serotype 14 is known to also
contribute significantly [111]. Other serotypes have been reported in single cases, including serotypes
1, 5, 9, 16, 21, and 31. The serotype is determined by the antigenic properties of the CPS of S. suis,
which is encoded by multiple genes located in a single locus. The cps gene locus can be exchanged
between S. suis of different serotypes, and in a study from The Netherlands, it was shown that such
cps switch may lead to an increase in zoonotic potential. Zoonotic S. suis serotype 2 strains of ST20,
isolated from human patients, were shown to be genetically highly related to serotype 9 strains of
ST16. S. suis ST16 isolates have never been isolated from human patients but are highly implicated in
invasive disease in pigs in The Netherlands [26]. The serotype 2 CPS appears to induce very little to
no protective immunity, as was illustrated by a case of reinfection with S. suis serotype 2 in a Dutch
slaughterhouse worker [112].
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In addition to cps locus acquisition, loss or acquisition of other genes or loci may contribute to
changes in zoonotic potential. For example, the S. suis ST20 strains acquired not only the serotype 2 cps
locus but also a prophage carrying a type 1 Restriction-Modification (R-M) system (SsuCC20p) [113].
Such R-M systems have previously been shown to regulate gene expression through changes in
methylation, driven by the phase variation of the specificity unit of the system [114]. Further analysis
of this system in our lab indicates that it is indeed phase variable and that this variation results in
differences in colony morphology. This observation suggests that S. suis ST20 strains may have acquired
the ability to adapt to specific niches through the acquisition of a R-M system that can regulate CPS
and/or other surface exposed molecules gene expression (manuscript submitted).
Ingestion of contaminated food items is an important route of infection with S. suis, especially
in Southeast Asia. We have previously shown that the CPS modulates the interaction of S. suis with
intestinal epithelial cells in vitro. Using human Caco-2 cells and porcine IPEC cells, we observed that
serotype 2 strains adhered better to the human cells than serotype 9 strains, whilst the opposite was
observed for the porcine cells to which serotype 9 strains adhered better. In addition, non-encapsulated
mutant strains showed increased adherence, invasion, and translocation across Caco-2 cells, clearly
indicating a role for the CPS in intestinal infection in this experimental model [54]. To further study
S. suis intestinal translocation, models are needed that represent the intestinal tract better than colon
carcinoma cells in continuous culture. Recently, developments in stem cell research have made it
possible to grow intestinal organoids, which contain most cell types present in the proximal and distal
intestinal mucosa ex vivo. In addition, these organoids can now be grown in two-dimensional structures,
thus allowing study of translocation from lumen into mucosa, replicating intestinal translocation.
Initial experiments with Listeria monocytogenes, another Gram-positive pathogen known to cause
meningitis after intestinal translocation to the blood, demonstrated invasion and translocation patterns
similar to those observed in mouse models and mouse organoids. The zoonotic S. suis serotype 2 strain
BM407 was shown to translocate in this model as well, which makes it a promising model for future
study of intestinal infection with S. suis.
S. suis is likely to continue to emerge as a zoonotic pathogen, given the pressure to reduce
antimicrobial use in livestock because of the global threat of antimicrobial resistance. In addition, a
universally effective vaccine that can be used in pigs is not available. The global export of pigs that
carry multiple serotypes of S. suis will facilitate exchange of genetic material through recombination
and mobile genetic elements that may result in selective advantage and niche adaptation. It is
crucial to understand the factors that are involved in the ability to cause zoonotic infection and to
monitor if this may eventually result in S. suis strains that are human adapted and have become
human-to-human transmissible.
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Although we know that pathogens such as Streptococcus suis can be primary pathogens, causing
disease on their own, experimental and anecdotal evidence from the field indicate that the incidence
and severity of disease with certain pathogens like S. suis can increase when concurrent infections
with additional pathogens occur. The last National Animal Health Monitoring Survey conducted
by the Animal and Plant Health Inspection Service of the United States Department of Agriculture
indicated that respiratory disease is the primary cause of both nursery and grower/finisher deaths in
swine and that meningitis is the second most common cause of nursery deaths, which is primarily
caused by S. suis and Glaesserella (Haemophilus) parasuis. The top ten reported primary etiologies of
porcine respiratory disease cases at the Iowa State University diagnostic laboratory from 2013 to
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2014 were PRRSV, SwIV, Mycoplasma hyopneumoniae, Pasteurella multocida, S. suis, unspecified bacteria,
Actinobacillus suis, G. parasuis, Actinobacillus pleuropneumoniae, and Bordetella bronchiseptica, in that order.
From the 3330 cases where SwIV was identified as the primary etiology, 75% had secondary bacterial
pneumonia as well, with S. suis, P. multocida, G. parasuis, B. bronchiseptica, and Escherichia coli being the
most prevalent bacteria isolated (Courtesy of Dr. Phillip Gauger, Iowa State University). These results
were similar for cases where PRRSV was determined to be the primary aetiology. The term porcine
respiratory disease complex has been used to describe this common multifactorial respiratory disease
in swine that occurs as a result of polymicrobial infections, environmental stressors, and host factors
such age and immunological status.
Coinfections can be the result of multiple viruses, bacteria, or a combination of viruses and
bacteria infecting the pig at the same time or in close succession. Numerous examples of coinfections
with common swine viruses such as PRRSV, SwIV, porcine circovirus (PCV), and PRCV have been
detected in the diagnostic lab and investigated experimentally, and coinfections with these viruses
generally result in a more severe clinical disease outcome [115–118]. Similarly, coinfections with the
viruses mentioned above and common swine bacterial pathogens have often shown that these viruses
are potent initiators of secondary bacterial infections [34–42]. Primary bacterial pathogens can also
predispose to secondary bacterial colonisation and disease. Common examples of this in swine are
enzootic pneumonia, where M. hyopneumoniae predisposes to secondary pneumonia with P. multocida,
and atrophic rhinitis, where B. bronchiseptica predisposes to secondary infection with toxigenic strains
of P. multocida [119–121]. Our lab has also demonstrated that B. bronchiseptica can increase colonisation
with other bacteria such as G. parasuis [122]. Coinfections are not limited to only two pathogens and
can be complicated in nature. For example, we have shown that PRRSV alone predisposes pigs to
pneumonia with B. bronchiseptica but not with P. multocida whereas B. bronchiseptica can predispose
to nasal colonisation with P. multocida [34]. However, if the pig is infected with both PRRSV and B.
bronchiseptica, this can lead to pneumonia with P. multocida as well [123].
There are several mechanisms that contribute to increased susceptibility to secondary infection and
the enhanced disease that often occurs with coinfections, including disruption of the epithelial barrier
or alteration of the innate or adaptive immune responses by the primary pathogen, direct interactions
between or among the pathogens such as the formation of multispecies biofilms, disturbances to the
ecological niche such as the upper respiratory microbiota, or enhanced transmission. An example
of mechanical disruption would be the epithelial damage caused by pathogens such as SwIV or B.
bronchiseptica resulting in decreased cilial clearance and potentially in exposure of new attachment sites
and systemic invasion [124,125]. Decreased clearance of bacteria by professional phagocytes such as
alveolar macrophages and neutrophils can lead to secondary bacterial infections. Viruses such as PRRSV
and SwIV and bacteria such as B. bronchiseptica have been shown to affect phagocyte clearance though
such mechanisms as being directly cytotoxic, altering functions such as phagocytic or bactericidal
ability, or inhibition of recruitment of phagocytes to the site of infection [126–132]. These actions can
be due to direct interactions of the pathogens with the phagocytes or via altered cytokine production.
Often, there is an altered cytokine response to coinfections compared to the response seen with a
single pathogen resulting from signalling through multiple pattern recognition receptors that recognize
pathogen-associated molecular patterns. Frequently, this results in an amplified inflammatory response
with coinfections that lead to more severe clinical signs and enhanced lesions. We and others have
shown that coinfection with PRRSV, SwIV, or PRCV and bacteria such as B. bronchiseptica, S. suis, or G.
parasuis result in a greater incidence of disease, greater percentage of lung affected, more severe lesions,
and slower resolution of lesions than occuring with infection with the single pathogen alone, and this
is often correlated with an amplified pro-inflammatory cytokine response [35,39,43–45] (Brockmeier,
unpublished data).
Direct interactions among pathogens can lead to enhanced infection with secondary pathogens as
well. For example, it has been shown that SwIV can promote adherence, colonisation, and invasion of
S. suis due to interaction with the capsular sialic acid moiety present on some serotypes [52,53,133].
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It has also been demonstrated that certain species of bacteria such as Bordetella can enhance colonisation
of other bacterial species by a process called piracy of adhesins, whereby one bacterial species can
utilize adhesins secreted by another bacterial species to attach to host cells [134].
There has been a great deal of interest lately in examining the microbiome of the digestive and
respiratory tract and in determining if and how the local community of microbes might influence
gut and respiratory tract health and/or predisposition to infection. Studies currently or recently
performed have shown that infection with pathogens such as SwIV, PRRSV, and B. bronchiseptica results
in significant changes to the nasal microbial composition and significant increases in abundance of
certain genera, such as Actinobacillus and Streptococcus (Brockmeier, unpublished data). In addition,
antimicrobial usage typically used in swine production has been shown to result in similar changes to
the microbiota [135]. Further studies will be needed in order to determine whether these changes in
composition result in increased incidence of disease with pathogens such as S. suis.
Development of animal models that recapitulate the polymicrobial infections typically seen in
swine production facilities can be challenging but are needed in order determine the best intervention
strategies to prevent the clinical disease seen with coinfections. Many factors such as the virulence of
the pathogens, immune status, age of the pig, order and timing of exposure to the pathogens, and
possibly microbiome can all affect the success of developing a model that reproduces the polymicrobial
diseases that are seen on the farm. Once a model is developed, intervention strategies such as
vaccination, antimicrobials, or other biotherapeutics can be tested for their effectiveness at preventing
or treating disease outbreaks. For instance, with coinfection models that we have developed, we have
demonstrated that, for certain strains of PRRSV, vaccination can reduce the incidence of secondary
bacterial pneumonia [136]. Others have shown that a previous low dose challenge with S. suis used to
vaccinate pigs, but not previous PRRSV vaccination, resulted in a lower incidence of streptococcal
disease in a PRRSV/S. suis coinfection model [137].
In conclusion, the intensification of animal agriculture has resulted in the circulation of numerous
potential pathogens at any given time on swine farms, and coinfections are more likely the norm
rather than the exception. This can result in increased incidence and enhanced disease with certain
pathogens including S. suis. We are just beginning to determine the pathogenesis of these polymicrobial
infections and to develop suitable models for their study. However, continued study in these areas is
needed to be able to develop effective intervention strategies to prevent the effects of these diseases on
swine production.
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Coinfections with SwIV may affect the course of S. suis infections, as has been shown recently in a
precision-cut lung slice model and in immortalized cells [52,53]. However, the molecular mechanisms
underlying these coinfections are poorly understood. So far, it has been shown that the interaction
of SwIV hemagglutinins with capsular sialic acids of S. suis results in the binding of streptococci to
virus-infected cells [52,53]. This adherence mechanism seems to be even more efficient than binding
mediated by bacterial adhesins [52]. The enhanced adherence and colonisation efficiencies of S. suis
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observed after coinfection with SwIV affect also the subsequent tissue invasion. Furthermore, a
coinfection with SwIV provides an additional advantage because virus infection induces apoptosis
of virus-infected cells, which are mainly ciliated cells. It has been proposed previously that the loss
of these specialized cells enables bacterial pathogens to get access to subepithelial cells and, thus, to
spread to other parts of the host organism [138,139].
So far, the mechanisms that enable S. suis to invade mucosal surfaces are not well known.
A streptococcal protein that contributes to bacteria–host cell association is suilysin, though it is not
a typical adhesin as it is not cell-bound but secreted [48]. This cholesterol-dependent cytotoxin can
induce apoptosis, resulting in epithelial damage. In addition, it is able to mediate attachment of S. suis
to the surface of the respiratory epithelium [48,49]. It has been suggested that suilysin facilitates
the colonisation and the establishment of the initial stages of infection in pigs by promoting host
cell lysis and invasion of S. suis through the epithelium when bacteria have colonised the upper
respiratory tract [49,140]. Furthermore, S. suis lacking the suilysin-gene has been shown to be avirulent
in a mouse infection model when applied via the intraperitoneal route but virulent in pigs after
intravenous infection, which indicates that suilysin is not essential for S. suis to cause systemic infection
in pigs once the bacteria have entered the blood vessels [141]. Nevertheless, suilysin-negative clinical
isolates are also found frequently in swine populations worldwide [142,143]. The prevalent ratios of
suilysin-positive and suilysin-negative strains worldwide are varying, and not all virulent strains of
S. suis produce suilysin [142,143]. Therefore, analyzing the biological role of suilysin in different stages
of bacterial infection may help to better understand the pathogenesis of non-cytotoxic S. suis strains.
In a recent study, we applied highly differentiated primary porcine respiratory epithelial cells
grown under air–liquid interface conditions to analyse the contribution of SwIV to the virulence of
S. suis with a special focus on its cytolytic toxin suilysin [51]. We found that, during secondary bacterial
infection, suilysin of S. suis contributes to the damage of well-differentiated respiratory epithelial cells
in the early stage of infection, whereas cytotoxic effects induced by SwIV became prominent at later
stages of infection [51]. Prior infection by SwIV enhanced the adherence to and colonisation of porcine
airway epithelial cells by the wildtype S. suis strain and a suilysin-negative S. suis mutant in a sialic-acid
dependent manner. A striking difference was observed with respect to bacterial invasion. After bacterial
mono-infection, only wild-type S. suis showed an invasive phenotype whereas the mutant remained
adherent. When the epithelial cells were preinfected with SwIV, also the suilysin-negative mutant
showed invasion capacity [51]. As mentioned above, suilysin is known to be a virulence-associated
factor that facilitates S. suis invasion as shown for both immortalized cells and differentiated airway
epithelial cells [48,49]. The cytolytic activity of suilysin contributes significantly to this effect, as shown
in our previous study, in which a mutant expressing a point-mutated suilysin lacking cytolytic activity
was significantly less invasive than the wild-type streptococci [49]. Nevertheless, there was a significant
difference between the invasion rates of two mutants lacking only the cytotoxic activity or lacking
the whole protein [49]. This finding suggests that there may be invasion-promoting effects of suilysin
which do not depend on the cytolytic activity.
Taken together, suilysin-negative S. suis strains can become invasive in a coinfection scenario with
SwIV, which might explain why suilysin-negative strains can cause clinical infections. Finally, these
results may contribute to our understanding of viral–bacterial interactions on airway coinfections.
Appendix H
Proceeding from the 4th International Workshop on Streptococcus suis
Switching of capsular type impacts on Streptococcus suis virulence in mice and pigs
Masatoshi Okura 1, Jean-Philippe Auger 2, Tomoyuki Shibahara 3,4, Guillaume Goyette-Desjardins 2,
Marie-Rose Van Calsteren 5, Fumito Maruyama 6,7, Makoto Osaki 1, Mariela Segura 2,
Marcelo Gottschalk 2, and Daisuke Takamatsu 1,8
Pathogens 2020, 9, 374 25 of 39
1 Division of Bacterial and Parasitic Diseases, National Institute of Animal Health, National Agriculture
and Food Research Organization, Tsukuba, Japan
2 Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada
3 Division of Pathology and Pathophysiology, National Institute of Animal Health, National Agriculture
and Food Research Organization, Tsukuba, Japan
4 Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka
Prefecture University
5 Saint-Hyacinthe Research and Development Centre, Agriculture and Agri-Food, Saint-Hyacinthe,
Quebec, Canada
6 Microbial Genomics and Ecology, Office of Industry-Academia-Government and Community
Collaboration, Hiroshima University
7 Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, Chile
8 The United Graduate School of Veterinary Sciences, Gifu University, Gifu, Japan
Streptococcus suis is an important zoonotic pathogen causing various diseases in pigs and
humans [1]. Strains of S. suis can be classified into different serotypes on the basis of antigenic
differences in CPS [1,2]. Among more than 30 serotypes, serotype 2 is the most frequently associated
with clinical cases in both pigs and humans [2]. Meanwhile, CPS of S. suis is known to be a major
virulence factor contributing to protection against phagocytosis by host cells [3]. In addition, several
studies demonstrated attenuated virulence of the isogenic non-encapsulated mutants by in vivo murine
and porcine models [3]. However, almost all of the studies used serotype 2 strains, and little is known on
the roles of CPSs of other serotypes as a virulence factor. Therefore, it is unknown whether differences
in serotype themselves (i.e., differences in CPS structure) directly affect S. suis virulence. To answer this
question, we experimentally generated six serotype-switched mutants using the serotype 2 strain P1/7
(P1/7cps2to3, P1/7cps2to4, P1/7cps2to7, P1/7cps2to8, P1/7cps2to9, and P1/7cps2to14) by exchanging
the CPS synthesis gene cluster for those of serotypes 3, 4, 7, 8, 9, and 14, respectively, and compared
their virulence in mice and pigs. In mice, S. suis strain/mutants were intraperitoneally inoculated
at a final dose of 1 × 107 CFU to groups of 10–11 six-week-old C57BL/6 mice for survival (14 days
postinfection) and blood bacterial burden (24, 48, and 72 h postinfection) evaluation. P1/7cps2to8,
expressing serotype 8 CPS, showed higher mortality and blood bacterial load than serotype 2 strain
P1/7, with all infected mice succumbing within 24 h from septic shock. The virulence of P1/7cps2to7,
P1/7cps2to9, and P1/7cps2to14 were equivalent to that of P1/7 (survival: approximately 40% of infected
animals), whereas the mortality of mice inoculated with P1/7cps2to3 and P1/7cps2to4 was remarkably
reduced compared with that of P1/7, with 70% and 100% of survived animals, respectively. In pigs, one
hour after intranasal administration of 1% acetic acid, groups of 4–5 crossbreed specific pathogen-free
piglets aged 5 weeks were intranasally inoculated with approximately 2 × 109 CFU of respective S. suis
strain/mutants to monitor for clinical signs for 7 days postinoculation and to evaluate bacterial recovery
from infected animals. Clinical signs such as lameness, shivering, and dysstasia were observed only
with P1/7, P1/7cps2to7, and P1/7cps2to8 strains. Inoculated strains were recovered from several
major organs and blood from the pigs showing clinical signs infected with P1/7 and P1/7cps2to8,
while P1/7cps2to7 was recovered only from brain. In addition, P1/7cps2to8 was also recovered from
several major organs of experimentally infected but clinically healthy pigs. Except for one of the pigs
infected with P1/7cps2to14, in which the inoculum was recovered from several major organs and blood,
recovery of infected bacteria from blood or more than two of major organs was not observed in infected
pigs that showed no clinical signs during the experiment period. Taken together, our data indicate
that serotype switch in S. suis has different impacts on the virulence in mice and pigs depending
on switched serotypes. This suggests that CPS structure itself is an important factor in determining
levels of S. suis virulence, although further studies are needed to elucidate the mechanisms behind the
observed phenomena.
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Bacterial pathogens can and do evolve against treatments. The most obvious of such change
is the acquisition of resistance to antimicrobials. Even by the early 1980s, large numbers of S. suis
isolates from pigs had become resistant to tetracycline and macrolide classes of antibiotics [144], and
more recently, some isolates have become resistant to all classes of antibiotics used in pigs [145,146].
Resistance also arises against vaccines [147]. S. suis bacterin vaccines consist of strains isolated from
a herd, which are then inactivated and administered as treatment. There has been no consistent
evidence that bacterin vaccines give cross-protection against different strains of the bacterium, and so
vaccinated animals can develop S. suis clinical disease [148]. The failure of these S. suis vaccines is
therefore different from acquired resistance. However, treating only a subpopulation of S. suis could
lead to vaccination-driven strain replacement or to vaccination-driven bacterial evolutionary change
(acquired vaccine resistance). These processes will decrease vaccine effectiveness over time. Given our
knowledge of the ecology and genetics of S. suis, it is important to consider how S. suis might respond
and evolve against new and existing treatments and whether we can use this information to design
treatments that are more “evolution-proof”.
The lack of cross-protection of bacterin vaccines speaks to the considerable genetic diversity of
S. suis, which makes it a challenge to design a universal vaccine. A universal vaccine would need
to contain an antigen that is highly conserved at the protein level across the whole S. suis species.
Unfortunately, less than half the proteins found in an average S. suis strain are conserved across the
species at more than 80% protein identity [64]. This is without considering that lineages of “diverse
S. suis”, which cause typical S. suis disease, are found colonising the same niches and freely recombine
with S. suis [84]. Their limited conservation with “normal S. suis” at the amino acid level substantially
decreases the number of species-wide conserved proteins [84]. It is doubtful that a suitable universal
antigen exists, but if it did and was able to induce mucosal immunity (i.e., immunity against carriage of
S. suis), we could eliminate S. suis from pig populations and deliver herd immunity effects, protecting
pigs that had not been vaccinated. S. suis is, however, an extremely common commensal, found in
the tonsils of most and perhaps all pigs. Wiping out a ubiquitous part of the microbiome may have
unforeseen effects on other common opportunistic pathogens inhabiting the upper respiratory tract of
pigs, such as Haemophilus parasuis and Actinobacillus pleuropneumoniae.
Another more feasible strategy would be to selectively target strains that are more prone to causing
clinical disease. Our lab and others have shown many trends in genetic and phenotypic differences
between strains isolated from the upper respiratory tract of pigs without S. suis clinical signs (hereafter
“nonclinical”) and strains isolated from the lungs or systemic sites of pigs with S. suis clinical signs
(hereafter “clinical”) (Figure A1) [64,145,146,149]. Overall, the genetic diversity of clinical S. suis is less
than that of nonclinical strains, implying that we need not design a universal vaccine to eliminate the
majority of S. suis disease.
One obvious candidate for a vaccine targeting clinical strains is the CPS outer layer of S. suis.
This is because the majority of clinical strains have a capsule (Figure A1), which helps them to survive
in the blood [150]. Indeed, polysaccharide capsules are widely used or considered in treatments
for other streptococcal pathogens. However, capsules evolve rapidly. Because they are genetically
diverse, multiple different polysaccharides are needed in a vaccine to target different strains. As with
bacterin S. suis vaccines, there will be vaccine failure if we do not target all CPS types. Not only that,
we may get vaccination-driven strain replacement of the population, and this can reduce the overall
vaccine effectiveness over time as non-vaccine types rise in frequency. This has been suggested as a
Pathogens 2020, 9, 374 27 of 39
reason for the rise in non-vaccine strains in invasive pneumococcal disease [151]. In addition to their
diversity, capsule loci are often recombination “hot-spots”, and this gives rise to frequent and easy
capsule “switching” between strains [152]. This means that highly invasive strains can quickly evolve
non-vaccine CPS types, leading to acquired vaccine resistance. For these reasons, it would be desirable
to identify alternative virulence candidates. Proteins with higher conservation and in regions of the
genome with greater syntenic preservation and less recombination would be obvious choices.
There may also be inherent problems with targeting only clinical strains. Despite the worldwide
use of beta-lactams in pigs for over 50 years, the majority of clinical S. suis remain sensitive to these
antibiotics. However, beta-lactam resistant strains do exist and are primarily found in commensal sites
(Figure A1). These resistant strains could spread if the susceptible (clinical) strains were wiped out.
The problems discussed above—strain replacement/evolution—will be reduced if we exclusively
induce systemic immunity (i.e., immunity against systemic infection that has no effect on colonisation).
This is because S. suis is an opportunistic pathogen and so commensal sites (and not clinical sites) are
the site of transmission of S. suis to other pigs. If the S. suis flora in commensal sites remain unaffected
by vaccination, transmission dynamics remain unchanged. We would still get vaccine failure for any
strains that were not targeted by the vaccine, but the effectiveness of this vaccine will not decrease over
time. Unfortunately, systemic immunity may be less successful in protecting against S. suis disease
than mucosal immunity. For example, pneumococcal vaccines triggering systemic immunity with
protection against invasive disease appear to be less effective against pneumonia [153].
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To summarise, existing data on S. suis allow us to draw some important conclusions. First, if we do
not have a universal target against all S. suis, we cannot rule out strain replacement/evolution, leading
to decreased vaccine effectiveness over time, with potential downstream effects on antimicrobial
effectiveness. Second, and more positively, S. suis strain replacement/evolution should not be a problem
with vaccines that induce systemic but not mucosal immunity. These are considerations that we can
bear in mind in designing new vaccines but are minor in view of the many other existing challenges in
bringing an effective S. suis vaccine to market.
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Streptococcus suis is an early coloniser of the upper respiratory tract of piglets, which are commonly
colonised by S. suis from birth. In fact, piglets can get colonised as soon as they pass through the birth
canal, since S. suis is found in the sow vagina. Virulence of the S. suis strains and the immunity of
the animals influence the outcome of the infection. S. suis infections are one of the main causes of
antimicrobial usage in piglets. Due to the young age of the piglets affected and the lack of an effective
commercial vaccine, many farms use metaphylactic perinatal antimicrobials to control of S. suis disease.
A similar situation is found with the diseases produced by other early colonisers of piglets, such as
Haemophilus parasuis and Mycoplasma hyorhinis. Nowadays, public and private institutions are urging
for a significant reduction in antimicrobial use, since the emergence of drug resistances has become a
major health problem. An additional problem of antimicrobial usage is that these treatments can also
affect the beneficial bacteria of the microbiota.
Microbiota is the community of microorganisms that live on different tissues on all multicellular
organisms. Pathogen exclusion is an important role of the microbiota [154], and it can be achieved by
competition or by induction of the correct maturation of the immune system. Thus, the microbiota
is essential for health, and this has changed our current view on antimicrobials, since they can have
deleterious effects on favourable bacterial populations [155]. However, the use of metaphylactic
antimicrobials at early stages of life is still in practice in porcine production.
Clinical observations indicate that overuse of antimicrobials at an early age can have a harmful
effect later in the pigs’ health [156]. In an attempt to understand this phenomenon, the outcome of
perinatal antimicrobial treatment on the nasal microbiota at weaning was studied in two farms [157].
These two farms reported polyserositis cases in the nursery phase and used antimicrobials during
the lactation phase for disease control. The nasal microbiota was determined when antimicrobial
treatment was used early in life and later when antimicrobial treatments were eliminated during the
lactation period. Elimination of perinatal antimicrobials resulted in an increase in bacterial diversity
in the nasal microbiota at weaning. The specific analysis of the relative abundance of Streptococcus
showed a limited reduction of this genus at weaning after removal of antimicrobials in both farms.
However, interpretation of this information is not straightforward since the genus Streptococcus includes
several species, some of which cannot be considered pathogenic. Furthermore, S. suis strains display
a wide variety of virulence capacity, complicating the interpretation of the result on streptococcal
abundance with respect to health consequences. Further analysis of the microbiota composition found
that the elimination of antimicrobials produced an increase in the relative abundance of Prevotella and
Lactobacillus and a decrease in Moraxella and Bergeyella in both farms. While Prevotella and Lactobacillus
are considered important components of a healthy microbiota, Moraxella and Bergeyella have been
reported to have pathogenic potential. In agreement, these changes in microbiota composition were
accompanied by an improvement of the piglets’ health and a higher productivity in the nursery phase.
Mortality (in one of the farms) and medication cost in the nursery (in both farms) were reduced,
indicating that management of lactation without perinatal antimicrobials had a beneficial impact
later in life. Thus, the changes observed after elimination of antimicrobials can be explained by the
consequent reduction of pathogenic genera and the simultaneous increase of beneficial bacterial genera,
together with the general increase in microbiota diversity, which has been widely associated with
improved health status.
A different study showed that perinatal ceftiofur administration delayed the colonisation by
S. suis and the pathogen load. However, a detailed analysis of the S. suis strains showed that different
strains were selected by the antimicrobial drug and that serovars associated with virulence were more
abundant in the nasal cavities of the treated piglets (unpublished results). While these results need
deeper analysis, they indicate that the precise effects of antimicrobials are difficult to predict.
Early medication with antimicrobials has to be carefully considered since antimicrobials interfere
with the establishment of the microbiota and, in consequence, with immune maturation and other
microbiota functions, which may have a lasting health effect later in life.
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Controlling S. suis in the field may require the use of autogenous vaccines since no other vaccines
are nowadays licensed in Europe. Obviously, the wide use of autogenous vaccines and cross-border
movement of animals vaccinated with autogenous vaccines is now a common practice within Europe.
Therefore, harmonising quality of these products has been considered necessary by the Coordination
Group for Mutual Recognition and Decentralised Procedure—Veterinary (CMDv) and the national
competent authorities for Veterinary Medicinal Products (VMPs) in Europe.
Definitions:
The current European directive 2001/82 [158] that regulates VMPs defines autogenous vaccines
but does not provide any other requirements. Article 3(1) states that the directive shall not apply for
“Inactivated immunological VMPs which are manufactured from pathogens and antigens obtained
from an animal or animals from a holding and used for the treatment of that animal or the animals of
that holding in the same locality”. Article 4, about non-inactivated autogenous vaccines, says that the
Member States (MS) may provide that the directive shall not apply. In other words, the inactivated
autogenous vaccines fall under national legislation whereas live autogenous vaccines may be under
European regimen (so should be authorized as any other licensed vaccines) or national regimen
according to the MS decision.
In January 2019 a new legislation on VMPs has been adopted in the European Union, the regulation
2019/6 [159], applicable in January 2022. In this new regulation, autogenous vaccines have an updated
definition and fall under European regimen. Article 2(3) of this regulation requires that some articles
of the regulation apply to “inactivated VMP manufactured from pathogens and antigens obtained
from an animal or animals in an epidemiological unit and used for the treatment of that animal or
those animals in the same epidemiological unit or for the treatment of an animal or animals in a unit
having a confirmed epidemiological link”.
Background:
In 2015, the CMDv started a work on autogenous vaccines and overviewed the different situations
and regulations in Europe [160]. The outcome was that European MS had various experiences and
backgrounds with respect to the autogenous vaccines manufacture and use. As an example, in France,
where only bacterial autogenous vaccines are allowed, the manufacturer should be authorized to
prepare the autogenous vaccine before marketing the autogenous vaccine.
The French agency authorizes the preparation based on four pillars:
- The preparation site (called establishment), authorized based on inspection and a technical dossier
- The qualified person, mentioned in the authorization as the person who prepares and releases
the product
- A positive list of bacteria and animal species, in annex of the license given to the manufacturer
and based on the lists of disease for which no authorized vaccines with marketing authorization
is available as an alternative. In cases when autogenous vaccine is needed when a vaccine is
already authorized but in lack of efficacy situation, the manufacturer should seek a derogation.
- A positive list of adjuvants, based on the adjuvants used by the manufacturer and in compliance
with the Maximum Residues Limit regulation.
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The French market is displayed in Figure A2.
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In 2015, the CMDv started a work on autogenous vaccines and overviewed the different 
situations and regulations in Europe [160]. The outcome was that European MS had various 
experiences and backgrounds with respect to the autogenous vaccines manufacture and use. As an 
example, in France, where only bacterial autogenous vaccines are allowed, the manufacturer should 
be authorized to prepare the autogenous vaccine before marketing the autogenous vaccine.  
The French agency authorizes the preparation based on four pillars: 
- The preparation site (called establishment), authorized based on inspection and a technical 
dossier 
- The qualified person, mentioned in the authorization as the person who prepares and releases 
the product 
- A positive list of bacteria and animal species, in annex of the license given to the manufacturer 
and based on the lists of disease for which no authorized vaccines with marketing authorization is 
available as an alternative. In cases when autogenous vaccine is needed when a vaccine is already 
authorized but in lack of efficacy situation, the manufacturer should seek a derogation.  
- A positive list of adjuvants, based on the adjuvants used by the manufacturer and in 
compliance with the Maximum Residues Limit regulation. 
The French market is displayed in Figure A2. 
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Recommendations paper and new veterinary regulation:
Then, the CMDv has prepared a recommendation paper [78] which deals with the manufacture,
the control, and the use of viral and bacterial autogenous vaccines in Europe. In the framework of the
new regulation, this paper will be updated in the coming years. The same locality has been defined
as the same and single rearing site, farm where the pathogen is present or multiple sites having an
epidemiological link. It has been clarified that groups of animals have an epidemiological link when
one of them is to be put in contact with pathogens it has never met before but which are present in
other group of animals raised in another rearing site or farm. The movement between sites should be
considered. It reflects the actual situation in Europe and current field practices in integrated systems
for poultry, fishes, and pigs especially. The introduction of the concept of epidemiological link allows
now the use of autogenous vaccines in parental lines or, for animals, prior introduction in fattening
sites where they will be in contact with new pathogens. In the new regulation, the concept is now
directly in the definition, article 2(3).
The paper states the following:
- Autogenous vaccines should be used only to solve an exceptional epidemiological situation, not
in replacement of the regular authorized VMP. It should be shown that no licensed immunological
VMP is available under the cascade prescriptions or that licensed immunological VMP have been
proved to be not efficacious for the specific situation.
- Specific pathogen should have been isolated in the locality, during an outbreak of the disease.
- The veterinarian should have made the diagnosis and is responsible of the administration. They
are also obliged to report any quality defects and adverse events as regulated by the provisions
for the Pharmacovigilance.
- Manufacture should be done under Good Manufacturing Practices (GMP) or GMP-like
requirements. The manufacturers should have been authorized, and the compliance with
the requirements is controlled by inspection. A qualified person should be designated to ensure
the quality of each batch. Transmissible Spongiform Encephalopathies’ (TSE) guidance should be
followed for the starting materials.
- A veterinarian should make the diagnosis, collect the antigen, and ensure the traceability whereas
an authorized competent site (a laboratory) should ensure the isolation and the identification.
- Starting materials should comply with the European Pharmacopoeia (Ph. Eur.) requirements;
must be sterile; and, if of biological origin, must comply with TSE and extraneous agents
requirements. Seed material should be pure, and inactivation should be validated.
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- Batches should be controlled for sterility, complete inactivation, and endotoxin, if relevant.
All these disposals are partially now in articles 94, 105, 106(5), and 123 of the new regulation
2019/6, whereas 70 adds the provisions that manufacture should be in accordance with the principles
of GMP and that guidelines for GMP should be developed for the autogenous vaccines.
Conclusion:
The autogenous vaccines in EU are a very interesting therapeutic tool to fight against diseases,
especially S. suis. The current and future regulatory framework ensure high quality for those products.
Safety and efficacy are not regulated. However, safety and efficacy of these products are better
demonstrated through field use and laboratory research.
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